Gene therapy for malignant glioma patients

Advances in Experimental Medicine and Biology

Volumn 451, Issue , 1998, Pages 505-509

  Puumalainen, Anu Maaria ^a   Vapalahti, Matti ^a   Ylä Herttuala, Seppo ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA; GROWTH INHIBITION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 0031724644     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5357-1_78     Document Type: Article

References (16)

1. Ammirati M, Galicich JH, Arbit E, Liao Y (1987): Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21:607-614.
2. Culver KW, Blaese RM (1994): Gene therapy for cancer. TIG 10:174-178.
3. Oldfield EH, Ram Z, Culver KW, Blaese RM, Devroom HL, Anderson WF (1993):Gene therapy for the treatment of brain tumors using intratumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 4:39-69.
4. Ram Z, Culver K, Oshiro E, et al (1995): Summary of results and conclusions of the gene therapy of malignant brain tumors: clinicl study. (Abstract). The 63rd Annual Meeting of the American Association of Neurological Surgeons, April 22-27, 1995, Orlando, USA.
5. Ylä-Herttuala S (1997): Gene therapy for cancer. In:Tumor Invasion: Biological, Clinical and Therapeutical Considerations. Eds. Mikkelsen, Bjerkvig, Laerum, Rosenblum, John Wiley & Sons. (In print).
6. Moolten FL (1994): Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1(4):279-287.
7. Thorsen F, Visted T, Lehtolainen P, Ylä-Herttuala S, Bjerkvig R (1997): Virus Production in a Replication Deficient Retrovirus Packaging Cell Line. Int. J. Cancer. (Accepted).
8. Yee JK, Miyanohara A, LaPorte P, Bouic K, Bums JC, Friedmann T (1994): A general method for the generation of high-titer, pantropic retroviral vectors: Highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. USA 91:9564-9568.
9. Poptani H, Puumalainen AM, Gröhn O, Loimas S, Kainulainen R, Ylä-Herttuala S, Kauppinen R: Monitoring Thymidine kinase and Ganciclovir-Induced Changes in Rat Malignant Glioma In Vivo by Nuclear Magnetic Resonance Imaging. Cancer Gene Therapy. Accepted.
10. Puumalainen AM, Turunen M, Loimas S, Vainio P, Vanninen R, Tyynelá K, Jänne J, Vapalahti M, Ylä-Herttuala S (1997): Thymidine kinase gene therapy and bystander effect in experimental rat glioma model in vivo. (Submitted).
11. Puumalainen AM, Vapalahti M, Agrawal R, Laukkanen J, Kossila M, Viita H, Vanninen R, Paljärvi L, Ylä-Herttuala S (1997): b-galactosidase gene transfer to human malignant glioma using retro- and adenovirus vectors. (Submitted).
12. Ylä-Herttuala S, Luoma J, Viita H, Hiltunen T, Sisto T, Nikkari T (1995): Transfer of 15-lipoxygenase gene into rabbit iliac arteries results in the appearance of oxidation-specific lipid-protein adducts characteristic of oxidized low density lipoprotein. J Clin Invest 95:2692-2698.
13. Bi WL, Parysek LM, Warnick R, Stambrook PJ (1993): In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum.Gene Ther. 4:725-731.
14. Laitinen M, Pakkanen T, Donetti E, et al. (1997): Gene transfer into the carotid artery using an adventitial collar. Human Gene Therapy 8:1657-1661.
15. Laitinen M, Zachary I, Breier G, Pakkanen T, Häkkinen T, Luoma J, Abedi H, Risau W, Soma M, Laakso M, Martin JF, Ylä-Herttuala S (1997): VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries. Human Gene Therapy. In press.
16. Ram Z, et al. (1994): In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. J Neurosurg. 80:535-540.